Mina Mar Marketing – Blog & Announcements

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire
NEW YORK, NY, Mar 08, 2010 (MARKETWIRE via COMTEX) — Hiru Corporation (PINKSHEETS: HIRU) announced earlier this month that their subsidiary Jiangxi RongYu Pharmaceuticals, posted over $4 million in gross profits on $24 million in gross revenues.

Jiangxi RongYu Pharmaceutical Group Co., Ltd is a leader in the Chinese naturopathic medicine market. Naturopathic medicine is a branch of medicine in which a variety of natural medicines and treatments are used to heal illness. China currently holds over 10% of this market, approximately $8 billion, with an expected doubling of the market in the next 5 years.

Jiangxi RongYu is in a position to capitalize on the growth with recent announcements that several of its products have been added to China’s National Essential Drugs List. All medicines placed on this list must be available to doctors and in stock in pharmacies and county hospitals throughout the country of China.

For more information, please visit www.minamargroup.net/our_clients.html